Lederfolat

Calcium folinate, the active ingredient in Lederfolat, is a folate analog presented as an oral formulation for oral use. It supplies reduced folate that bypasses dihydrofolate reductase inhibition, helping to restore normal folate‑dependent metabolic pathways. The drug is used to correct folate deficiency and to rescue patients from toxicity associated with methotrexate or 5‑fluorouracil chemotherapy.

GNH USA supplies Lederfolat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border distribution.

Lederfolat is a folate analog used to address conditions related to impaired folate metabolism or chemotherapy‑induced folate antagonism.

- Folate deficiency: restores normal folate levels and supports hematopoiesis. - Methotrexate toxicity: provides rescue therapy to reduce adverse effects of methotrexate treatment. - 5‑Fluorouracil toxicity: mitigates toxicity when 5‑FU is administered. - Folate‑related anemia: assists in correcting anemia caused by inadequate folate.

Adverse reactions may occur with Lederfolat use.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools that may be transient. - Headache: occasional mild headache. - Abdominal pain: discomfort in the stomach area. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Hypersensitivity reactions: including anaphylaxis or severe skin rash. - Hepatic enzyme elevation: significant increase in liver function tests. - Hematologic abnormalities: severe neutropenia or thrombocytopenia. - Renal impairment: reduced kidney function in susceptible patients. - Severe gastrointestinal bleeding: rare but serious.

Before prescribing Lederfolat, consider the following precautions.

- Assess renal function: adjust use in patients with impaired kidneys. - Monitor liver enzymes: watch for hepatic toxicity during therapy. - Check for hypersensitivity: discontinue if allergic reactions occur. - Use caution in cancer patients receiving antifolate chemotherapy: coordinate timing with oncologist. - Avoid in known folate hypersensitivity: contraindicated for individuals with documented allergy. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Lederfolat may interact with several medications.

Major Interactions (Avoid): - Methotrexate: calcium folinate can antagonize methotrexate's therapeutic effect if given concurrently. - Pemetrexed: may reduce the anticancer activity of pemetrexed. - High‑dose folic acid supplements: can interfere with intended rescue dosing.

Moderate Interactions (Monitor Closely): - Cytarabine: increased risk of toxicity when combined. - Trimethoprim: may heighten myelosuppression. - Phenytoin: can alter folate metabolism, requiring monitoring.